Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    -0.20 (-0.13%)
Bid:
153.20
Ask:
153.60
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM Trading Statement

13 May 2021 07:00

RNS Number : 4477Y
Elementis PLC
13 May 2021
 

Elementis plc

AGM Trading Statement

Strong first quarter performance, ahead of expectations

On track for improved financial performance and deleveraging

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 31 March 2021 and an update on current trading.

First quarter business performance

In the first quarter of 2021 Group performance has been strong and ahead of expectations. Revenue increased approximately 6% on the prior year period, which was largely before the impact of COVID-19, with the successful execution of self help actions augmented by improved underlying demand, customer restocking and currency tailwinds.

· Coatings revenue increased significantly on the prior year period with strong volumes across all geographies driven by new business wins, improved industrial coatings demand and customer restocking. Margins were robust with pricing actions offsetting raw material cost inflation.

 

· Personal Care performance was as expected, slightly below the prior year period, with customer restocking offset by continued weak category demand for cosmetics and anti-perspirant deodorants due to COVID-19 related social and travel restrictions. Margins were resilient and the start-up of our new plant in India is expected to commence in the third quarter.

 

· Talc performance was broadly in line with the prior year period with strong industrial talc growth, driven by the continued rebound in automotive demand and robust coatings sales, offset by weaker sales to paper end markets.

 

· Chromium revenue was in line with the prior year period due to improved demand and restocking across key industrial end markets such as automotive and leather tanning. While unit pricing was sequentially stable, margins were below the prior year period due to lower pricing outside of North America.

 

Cash generation in the first quarter was in line with expectations and the Group's business model remains highly cash generative.

 

Outlook

 

We have made a strong start to the year, with improved year on year profitability, driven by increased demand across industrial end markets. This positive momentum has continued into the second quarter and demand remains healthy. For the full year, we are confident that further steady demand improvement from H2 2020 levels coupled with our self help actions will drive improved financial performance, towards the top end of consensus expectations*, and a reduction in leverage.

 

 

Commenting on the performance, CEO, Paul Waterman said,

"We have made a good start to 2021 and are on track to deliver an improved financial performance and a reduction in leverage. We will continue to maintain our focus on self-help actions and in 2021 expect to deliver more than $30m of new business opportunities, over 20 new products and $10m of cost savings".

 

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson/David Allchurch Tel: 020 7353 4200

 

 

* Based on the company compiled consensus, the Board believes current market forecasts for 2021 adjusted operating profit to be in the range of $92m to $103m with an average of $97m.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQLLFFFELZBBD
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.